Anixa Biosciences 将来の成長

Future 基準チェック /06

Anixa Biosciencesは、9.5%と75.2%でそれぞれ年率9.5%で利益と収益が成長すると予測される一方、EPSはgrowで24.4%年率。

主要情報

9.5%

収益成長率

24.4%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	75.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	19 Nov 2024

今後の成長に関する最新情報

Recent updates

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Oct 06

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Apr 27

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Jan 13

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Sep 26

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

Aug 15

Anixa to get additional US patent linked to breast cancer vaccine technology

Jul 21

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jun 13

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

May 11

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Feb 24

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Oct 28

Our First Look At Anixa Biosciences

Sep 23

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

Jun 12

OntoChem assigns Anixa covid-19 drug discovery project to MolGenie

May 07

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jan 13

Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact

Dec 01

業績と収益の成長予測

NasdaqCM:ANIX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
10/31/2027	N/A	-17	-16	-16	1
10/31/2026	N/A	-16	-16	-16	1
10/31/2025	N/A	-15	-15	-15	2
10/31/2024	N/A	-13	-46	-11	2
7/31/2024	N/A	-12	-8	-8	N/A
4/30/2024	N/A	-12	-7	-7	N/A
1/31/2024	0	-11	-7	-7	N/A
10/31/2023	0	-10	-6	-6	N/A
7/31/2023	0	-11	-6	-6	N/A
4/30/2023	0	-11	-6	-6	N/A
1/31/2023	N/A	-12	-7	-7	N/A
10/31/2022	N/A	-14	-6	-6	N/A
7/31/2022	0	-14	-6	-6	N/A
4/30/2022	0	-16	-6	-6	N/A
1/31/2022	0	-15	-5	-5	N/A
10/31/2021	1	-13	-5	-5	N/A
7/31/2021	1	-11	-5	-5	N/A
4/30/2021	1	-9	-5	-5	N/A
1/31/2021	1	-10	-5	-5	N/A
10/31/2020	N/A	-10	-6	-6	N/A
7/31/2020	N/A	-10	-6	-6	N/A
4/30/2020	N/A	-9	-5	-5	N/A
1/31/2020	0	-9	-6	-5	N/A
10/31/2019	0	-12	-5	-5	N/A
7/31/2019	0	-15	-5	-4	N/A
4/30/2019	1	-18	-5	-5	N/A
1/31/2019	1	-17	-4	-4	N/A
10/31/2018	1	-14	-4	-4	N/A
7/31/2018	1	-10	-4	-4	N/A
4/30/2018	1	-7	N/A	-4	N/A
1/31/2018	0	-5	N/A	-4	N/A
10/31/2017	0	-7	N/A	-4	N/A
7/31/2017	1	-6	N/A	-4	N/A
4/30/2017	0	-6	N/A	-3	N/A
1/31/2017	0	-7	N/A	-4	N/A
10/31/2016	0	-5	N/A	-3	N/A
7/31/2016	0	-5	N/A	-4	N/A
4/30/2016	0	-6	N/A	-3	N/A
1/31/2016	0	-7	N/A	-4	N/A
10/31/2015	0	-1	N/A	1	N/A
7/31/2015	2	-3	N/A	2	N/A
4/30/2015	3	-1	N/A	2	N/A
1/31/2015	4	-2	N/A	3	N/A
10/31/2014	4	-10	N/A	-2	N/A
7/31/2014	3	-9	N/A	-3	N/A
4/30/2014	1	-12	N/A	-3	N/A
1/31/2014	0	-12	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ANIX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ANIX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ANIX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ANIX来年は収益がないと予測されています。

高い収益成長: ANIX来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ANIXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Anixa Biosciences 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased by 11% to US$10.50

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target increased to US$11.00

Consensus forecasts updated

Price target increased to US$9.00

Recent updates

Anixa Biosciences, Inc Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting

Now 20% undervalued

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Anixa Biosciences, Inc. Announces Submission of Protocol Amendment for CAR-T Trial

New minor risk - Share price stability

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Lead Independent Director recently bought US$84k worth of stock

Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology

Anixa Biosciences, Inc. (NasdaqCM:ANIX) announces an Equity Buyback for $5 million worth of its shares.

Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial

CEO, Chairman & Co-Chair of CBAB recently bought US$60k worth of stock

New major risk - Revenue and earnings growth

Anixa Biosciences, Inc. Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board

CEO, Chairman & Co-Chair of CBAB recently bought US$97k worth of stock

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Anixa Biosciences, Inc., Annual General Meeting, Mar 21, 2024

New minor risk - Share price stability

Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Anixa Biosciences, Inc. Appoints Mark A. Goldberg, Md, to Its Cancer Business Advisory Board

Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Anixa Biosciences, Inc. Establishes Cancer Business Advisory Board

Anixa Biosciences, Inc. Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial

Lead Independent Director exercised options to buy US$119k worth of stock.

Press Release: Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Now 38% undervalued after recent price drop

Price target increased by 11% to US$10.50

Anixa Biosciences, Inc., Annual General Meeting, Mar 09, 2023

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine

Insufficient new directors

Insufficient new directors

Anixa Biosciences Inc. Announces Commencement of Phase 1B Trial of Its Breast Cancer Vaccine At Cleveland Clinic

Lead Independent Director exercised options to buy US$197k worth of stock.

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Chairman & CEO exercised options and sold US$937k worth of stock

Anixa Biosciences Announces Treatment of First Patient in Its Ovarian Cancer Car-T Clinical Trial

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

Anixa to get additional US patent linked to breast cancer vaccine technology

Lead Independent Director exercised options to buy US$144k worth of stock.

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Price target increased to US$11.00

Anixa Biosciences, Inc. Announces Management Changes

Anixa Biosciences, Inc. Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Anixa Biosciences, Inc., Annual General Meeting, Mar 10, 2022

Anixa Biosciences, Inc., Annual General Meeting, Mar 10, 2022

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

Chairman recently bought US$60k worth of stock

Anixa Biosciences and Molgenie Announce That Their Covid-19 Compounds Are Expected to Be Effective Against the Omicron Variant

Lead Independent Director recently bought US$87k worth of stock

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Our First Look At Anixa Biosciences

Anixa Biosciences' Covid-19 Compounds Expected to Be Effective Against the Delta Variant

Anixa Biosciences, Inc. Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology